Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BNR
BNR logo

BNR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Burning Rock Biotech Ltd (BNR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
7.540
1 Day change
-7.26%
52 Week Range
41.720
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BNR is not a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock is showing a weak technical setup, there is no supportive proprietary buy signal, and the latest quarter showed declining revenue and a net loss. Based on the current data, the better call is to avoid buying now.

Technical Analysis

The technical trend is bearish. MACD histogram is -0.143, which is below zero and still negative, showing weak momentum. RSI_6 at 34.223 is near oversold but not yet a strong reversal signal. Moving averages are aligned bearishly with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Price closed at 8.52, below the pivot of 9.342 and just above support at 8.269, which means the stock is sitting close to support but without clear confirmation of a rebound. The stock trend model suggests modest near-term upside probabilities, but not enough to outweigh the broader weakness.

Positive Catalysts

  • ["Stock closed near the first support level, which may attract dip buyers.", "The stock trend model suggests a possible short-term rebound over the next day, week, and month."]

Neutral/Negative Catalysts

  • ["Q1 2026 revenue declined 14.7% year over year to $15.65 million.", "The company reported a net loss of RMB 17.5 million in Q1 2026.", "GAAP EPS for Q1 2026 was -$0.02.", "Insiders and hedge funds are both neutral, with no meaningful bullish accumulation.", "No recent AI Stock Picker signal and no recent SwingMax signal.", "No recent congress trading data available."]

Financial Performance

The latest reported quarter was Q1 2026. Financial performance weakened year over year, with revenue falling from $18.1 million in Q1 2025 to $15.65 million in Q1 2026, a 14.7% decline. The company also posted a net loss of RMB 17.5 million and GAAP EPS of -$0.02, indicating continued pressure on profitability and growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street upgrade/downgrade trend to support a bullish view. Based on the available data, Wall Street pros would likely view BNR cautiously: the positives are potential undervaluation after a decline and possible short-term technical stabilization, while the negatives are shrinking revenue, losses, bearish trend structure, and no clear insider or institutional buying. Overall, the pro view is weak to neutral rather than constructive.

Wall Street analysts forecast BNR stock price to rise
Analyst Rating
0
Wall Street analysts forecast BNR stock price to rise
Buy
Hold
Sell
0
Current: 8.130
sliders
Low
0
Averages
0
High
0
0
Current: 8.130
sliders
Low
0
Averages
0
High
0
Morgan Stanley
Annelies Vermeulen
Equal Weight -> Underweight
downgrade
AI Analysis
2026-01-06
Reason
Morgan Stanley
Annelies Vermeulen
Price Target
AI Analysis
2026-01-06
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley analyst Annelies Vermeulen downgraded Brenntag to Underweight from Equal Weight with a price target of EUR 50, down from EUR 63. The firm adjusted rating in the European business services group as part of its 2026 outlook. The analyst is cautious on the staffers and chemical distribution. Morgan Stanley's preferred stocks for 2026 are Experian, Diploma, Rentokil, Verisure, Bureau Veritas and ISS.
Berenberg
Hold
downgrade
2025-12-10
Reason
Berenberg
Price Target
2025-12-10
downgrade
Hold
Reason
Berenberg lowered the firm's price target on Brenntag to EUR 48 from EUR 51 and keeps a Hold rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BNR
Unlock Now

People Also Watch